Heart Failure Research Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Am J Physiol Heart Circ Physiol. 2012 Nov 1;303(9):H1085-95. doi: 10.1152/ajpheart.00191.2012. Epub 2012 Aug 31.
One of the major challenges in cardiovascular disease is the identification of reliable clinical biomarkers that can be routinely measured in plasma. MicroRNAs (miRNAs) were recently discovered to circulate in the bloodstream in a remarkably stable form. Because of their stability and often tissue- and disease-specific expression and the possibility to measure them with high sensitivity and specificity, miRNAs are emerging as new diagnostic biomarkers. In this review we will provide an overview of the potential of circulating miRNAs as biomarkers for a wide range of cardiovascular diseases such as coronary artery disease, myocardial infarction, hypertension, heart failure, viral myocarditis, and type-2 diabetes mellitus. Furthermore, we will discuss the challenges with regard to further validation in large patient cohorts, and we will discuss how the measurement of multiple miRNAs simultaneously might improve the accuracy of the diagnostic test.
心血管疾病的主要挑战之一是确定可靠的临床生物标志物,这些标志物可以在血浆中常规测量。最近发现 microRNAs (miRNAs) 以一种非常稳定的形式在血液中循环。由于它们的稳定性和通常组织和疾病特异性表达,以及高灵敏度和特异性测量的可能性,miRNAs 作为新的诊断生物标志物正在出现。在这篇综述中,我们将概述循环 miRNAs 作为多种心血管疾病的生物标志物的潜力,如冠状动脉疾病、心肌梗死、高血压、心力衰竭、病毒性心肌炎和 2 型糖尿病。此外,我们还将讨论在大型患者队列中进一步验证的挑战,我们还将讨论同时测量多个 miRNAs 是否可能提高诊断测试的准确性。